Centessa Pharmaceuticals CEO Touts ORX750 as Best-in-Class as Registration Studies Nearing Start [Yahoo! Finance]
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Yahoo! Finance
ORX750 Phase 2 early cohorts showed promising signals — 20-minute placebo-adjusted MWT improvement in NT1 (1.5 mg) with ESS dropping 18?5 and an 87% cataplexy reduction, 10-minute MWT change in NT2 (4 mg), and clinically meaningful, statistically significant effects in IH — and Centessa is testing substantially higher doses. Centessa is positioning ORX750 as a “best-in-class” orexin-2 agonist focused on efficacy and duration of action, plans a Phase 2 update this quarter and aims to start data-driven registration studies “this quarter,” while retaining the option to continue dose escalation and add higher doses into registrational plans. The company sees a large commercial opportunity (company estimate ~$18 billion across NT1/NT2/IH), is beginning to build a commercial team, and is evaluating pricing/commercial positioning and broader exploratory endpoints (cognition, executive function, brain fog) to support market uptake. Interested in Centessa Pharmaceuticals PLC Sponsored A
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals Teases ORX750 Phase II Update, Registrational Study Start at Conference [Yahoo! Finance]Yahoo! Finance
- Forget Centessa Pharmaceuticals: This Rare-Disease Specialist Has a Superior Portfolio and Pipeline [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals (CNTA) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Centessa Pharmaceuticals (NASDAQ:CNTA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $40.00 price target on the stock.MarketBeat
- Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire
CNTA
Earnings
- 8/12/25 - Miss
CNTA
Sec Filings
- 3/18/26 - Form 4
- 3/17/26 - Form 144
- 3/16/26 - Form 4/A
- CNTA's page on the SEC website